M.D., M.B.A., VP, Medical Affairs, Oncology, Natera
Biography
Dr. Alexey Aleshin has led the oncology clinical development efforts at Natera, Inc. since 2018. Prior to this, he worked on the various novel ctDNA technologies while at Stanford University. He remains a clinical adjunct faculty in the division of Hematology at Stanford, where his work focuses on novel diagnostics assays for treatment decision support in hematologic malignancies. He received a B.A. in Statistics from UC Berkeley and his M.D./M.B.A. degrees at UCLA. He completed his clinical training in internal medicine and hematology/oncology at Stanford University.
Talk
The Emerging Role of ctDNA for Molecular Residual Disease (MRD) Assessment and Recurrence Monitoring
In this session we will take a closer look at the expanding role of ctDNA for molecular residual disease assessment (MRD) and treatment response monitoring in patients with solid tumors and how these assays may be integrated into clinical practice to improve patient management.
Session Abstract – PMWC 2022 Silicon Valley
Alzheimer’s disease is one of our nation’s most significant threats, with devastating impacts on patients and their families. This session will explore a new approach called neurodiagnostic therapies, a methodology fundamentally enabled by ultrasensitive biomarker measurements that allow visibility to neurological disease in individuals before they are symptomatic. This allows treatment to be administered at a more optimal stage, to improve therapeutic effectiveness and by extension, patient outcomes.
During this presentation, attendees will learn how this new approach can provide early treatment to ultimately accelerate disease detection and improve outcomes, in addition to creating viable and credible evidence for the healthcare system to adopt it with coverage to facilitate frictionless access.
